Publications by authors named "Yefang Kang"
Wound infections have gradually become a major threat to human health. Recently, covalent organic frameworks (COFs) have shown great potential in antibacterial and wound healing; however, difficult biodegradability and long-time retention limit their further application. Herein, biodegradable COFs containing porphyrin backbones and hypoxia-sensitive azobenzene group, namely, HRCOFs, are fabricated for photodynamic therapy (PDT) and photothermal therapy (PTT) of wound infection.
View Article and Find Full Text PDF[Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with Mutation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2024
Article Synopsis
- - The study examined gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML) patients, focusing on how these mutations influence clinical characteristics and patient outcomes.
- - Among 151 newly diagnosed CN-AML patients, 36.42% tested positive for specific mutations, with 74.55% of them having additional co-mutations. The most frequent mutated genes included various transcription factors and signaling pathways.
- - Results indicated that patients with certain gene mutations had distinct clinical features, such as lower platelet counts and higher proportions of bone marrow blasts, suggesting that these genetic variations could play a significant role in prognosis and treatment approaches.
Introduction: GATA binding protein 2 (GATA2) gene, involved in progression of hematologic malignancies and various solid tumors, is a susceptibility gene for inherited acute myeloid leukemia (AML). However, the influence of its single-nucleotide polymorphisms (SNPs) on AML remains unknown.
Methods: We used allele-specific PCR to genotype GATA2 rs2335052 and rs78245253 in 159 newly diagnosed AML (non-M3) patients and 300 healthy volunteers, and all of participants came from China.
Introduction: CEBPA mutation is a common mutation in normal karyotype AML. CEBPAdm AML has been recognized as a separate entity, but there is still controversy to the prognosis of CEBPAsm patients.
Methods: A total of 151 newly diagnosed cytogenetically normal AML patients treated at the Second Hospital Center of Shanxi Medical University from February 2017 to December 2019 were the subjects of the study.